SciSparc unit NeuroThera and Clearmind file Hong Kong patent for combination depression therapy

SciSparc Ltd. (SPRC) — SciSparc said NeuroThera Labs, a roughly 75%-owned subsidiary, filed a patent application in Hong Kong under its collaboration with Clearmind Medicine covering a combination treatment for major depressive disorder.

The candidate pairs Clearmind's proprietary MEAI (5-methoxy-2-aminoindane) with NeuroThera's palmitoylethanolamide (PEA). The filing extends an ongoing IP-building effort between the two microcap developers around non-classic psychedelic compounds.

Source: globenewswire.com

For the rest of that week's sector news, read our week in review.